US 11110082
Tyrosine kinase inhibitors
granted A61KA61K31/4545A61K31/519
Quick answer
US patent 11110082 (Tyrosine kinase inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K31/4545, A61K31/519, A61P, A61P35/00